Scisparc ltd SPRC.US Overview Analysis
SPRC AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
SPRC Current Performance
12.90%
Scisparc ltd
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to SPRC
- FEMY Femasys incValue 3Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
SPRC Profile
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.